Developer docs
API playgroundTry for free, no card

Search company profiles

Beckley Foundation

Full company profile

uuid000sv72

Namestring
Beckley Foundation
Legal namestring
Beckley Foundation
Company typeenum
Private
Founded yearint
1998
Descriptiontext

The Beckley Foundation is a UK-registered non-profit charity (SC033546) founded in 1998 by Amanda Feilding, headquartered at Beckley Park, Oxford. Its scientific programme initiates, designs, and conducts research into the effects of psychoactive substances on the brain, with a particular focus on psychedelic compounds including LSD, psilocybin, ayahuasca/DMT, MDMA, and cannabis. The foundation's core technology stack combines neuroimaging modalities — fMRI, MEG, and optogenetic electrophysiology — with clinical trial design and novel research methodologies such as self-blinded microdosing surveys. It runs its flagship work through a long-standing partnership with Imperial College London (the Beckley/Imperial Research Programme, co-founded with Prof David Nutt in 2008), and maintains a network of more than 15 named university collaborations spanning the UK, continental Europe, the US, the Caribbean, and Brazil.

The foundation has produced over 35 peer-reviewed publications in high-impact journals including PNAS, Nature, Lancet Psychiatry, and Current Biology, including the world's first brain imaging study of the human brain on LSD (published 2016) and pioneering psilocybin trials for treatment-resistant depression showing 67% of patients in remission one week post-treatment. Its second core activity is drug policy reform advocacy: it has published major policy reports (Roadmaps to Regulation, Global Cannabis Commission), orchestrated open letters signed by world leaders and Nobel laureates, and holds a flagship advisory role with the Jamaican government on national cannabis regulation.

The business model is donation-funded non-profit: the foundation states that 'our ground-breaking work relies entirely on donations.' It currently reports paused receipt of donations. It does not sell products or services commercially; revenue derives from individual donations, crowdfunding, and research grants (e.g., a UK Medical Research Council grant for a Phase I psilocybin trial). Commercial activities bearing the Beckley name (Beckley Retreats, Beckley Psytech) operate as separate legal entities and are not part of the foundation itself. The foundation's customer base, in the conventional sense, is global and distributed across 40+ donor countries, with a small number of episodic government advisory relationships.

Short descriptiontext

The Beckley Foundation is a UK non-profit (founded 1998) that initiates and funds psychedelic neuroimaging and clinical research in collaboration with leading universities, while advocating for evidence-based drug policy reform globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic research, drug policy reform, neuroimaging studies, clinical trials, cannabis regulation
Industry1 code
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Scientific Research and Policy Advocacy
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Beckley Foundation initiates, designs, and conducts scientific research into the effects of psychoactive substances on the brain and consciousness, using neuroimaging technologies such as fMRI and MEG. It develops therapeutic protocols for treatment-resistant mental health conditions involving psilocybin and other psychedelics, and produces evidence-based drug policy analysis for governments and international bodies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 67% of treatment-resistant depression patients achieved complete remission one week after psilocybin treatment, with 42% remaining depression-free after 3 months (patients had suffered from depression for average of 18 years)
+3 more records
Product overview1 text field

The Beckley Foundation is a UK-based non-profit charitable organization (registered SC033546) focused on psychedelic research and drug policy reform. The foundation does not offer commercial products or services. Its activities include conducting and funding scientific research into psychedelics (LSD, psilocybin, DMT, MDMA, cannabis), publishing research findings, advocating for drug policy reform, hosting conferences and events, and providing educational resources through its website, podcasts, newsletters, and publications.

Product and service2 records
1Beckley/Imperial Psychedelic Research Programme
CategoryScientific Research
2Psilocybin-Assisted Psychotherapy Protocol
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership24 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

Co-founded the Beckley/Imperial Psychedelic Research Programme with Prof David Nutt in 2008. This flagship collaboration has produced world-first neuroimaging studies including the first brain imaging study of LSD and pioneering psilocybin clinical trials for treatment-resistant depression. The programme has resulted in over 35 publications in high-impact journals.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Initial collaboration began with Prof David Nutt at University of Bristol in 2005 before he moved to Imperial College London. Research focused on cannabis and psychedelics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with UCL on cannabis research, including comparing effects of different cannabis strains with varying THC/CBD ratios using brain imaging technology. Also working on Jamaican cannabis research with University of the West Indies.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Listed as a key collaboration partner in psychedelic research within the foundation's network of leading research institutions.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Listed as a key collaboration partner in psychedelic research within the foundation's network of leading research institutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr Jordi Riba focusing on ayahuasca research. This programme discovered that ayahuasca alkaloids stimulate neurogenesis in neural stem cells.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Co-hosted Psychedelic Science 2017 conference in Oakland, California together with MAPS. This major international scientific conference brought together the international psychedelic research community.

8Jamaican Ministry of Justice
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Amanda Feilding was invited by Minister Mark Golding in 2015 to advise the Ministry of Justice on formation of balanced policies for cannabis industry regulation in Jamaica. This advisory role has shaped Jamaica's pioneering approach to cannabis regulation.

beckleyfoundation.org
9Jamaican Ministry of Industry, Investment & Commerce
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Partnership with the Ministry on the conference 'Jamaica's Regulated Cannabis Industry: First Steps' and ongoing advisory work on developing cannabis regulation frameworks.

beckleyfoundation.org
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration planned for investigating biochemical composition of Jamaican cannabis landrace strains and identification of strains with optimal medical benefits.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborating with Jamaica's Cannabis Licensing Authority as part of advisory work on developing the regulated cannabis industry framework.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

16Beckley/Sechenov Institute Research Programme (Russia)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

beckleyfoundation.org
17Medical Office for Psychiatry and Psychotherapy, Solothurn
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

beckleyfoundation.org
18Madrid Computense University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

beckleyfoundation.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions focusing on ethnobotanical substances.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner in the Beckley Foundation's network of research institutions.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Professor Charles Nesson from Harvard Law participated in the Beckley Foundation delegation to UNGASS and conducted interviews on drug policy issues.

Strategic tierMinorTypeOthers
Description

Crowdfunding platform used for the world-first LSD brain imaging study campaign in 2015, raising £25,000 in 45 days.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based non-profit funding psychedelic (especially psilocybin) research at academic institutions. Directly comparable funder/research-catalyst role within the psychedelic ecosystem.

2Drug Science
TypeEmerging player
Description

UK-based independent scientific body chaired by Prof David Nutt (Beckley's principal collaborator). Closely adjacent on drug science and policy reform, with overlapping scientific leadership.

TypeDirect peer
Description

US-based non-profit conducting psychedelic clinical research and drug policy advocacy. Direct peer on both research (psychedelic-assisted therapy, MDMA for PTSD) and policy reform dimensions, and an existing Beckley co-host of Psychedelic Science 2017.

4Johns Hopkins Center for Psychedelic and Consciousness Research
TypeDirect peer
Description

Academic psychedelic research centre that is a listed Beckley partner and produces parallel psilocybin clinical trials. Comparable scope (psilocybin for depression, addiction, smoking cessation) and publication output.

TypeDirect peer
Description

Co-hosts the flagship Beckley/Imperial Research Programme; conducts neuroimaging and clinical psychedelic studies with the same principal investigators (Nutt, Carhart-Harris). Operationally the most overlapping peer.

TypeDirect peer
Description

Non-profit psychedelic research sponsor focused on psilocybin for major depressive disorder. Comparable mission, non-profit structure, and clinical trial sponsorship model.

TypeEmerging player
Description

Commercial psychedelic medicine company spun out of the Beckley ecosystem, led by Cosmo Fielding Mellen (Amanda Feilding's son). Operationalises psychedelic research into commercial drug development — adjacent mission, separate legal entity.

TypeBroad incumbent
Description

Publicly listed psychedelic therapy company developing psilocybin for treatment-resistant depression. Comparable clinical target; operates at substantially larger commercial scale than Beckley's research programmes.

9MindMed
TypeBroad incumbent
Description

Publicly listed psychedelic and digital therapeutic company developing LSD, MDMA, and DMT-based therapies. Competes for talent, partnerships, and policy influence in the same research domain.

TypeDirect peer
Description

Global network of NGOs working on drug policy reform. Closely aligned on the policy-advocacy dimension of Beckley's mission and a frequent collaborator at UN and government forums.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beckley Foundation

Scientific Research and Policy Advocacybeckleyfoundation.org

The Beckley Foundation is a UK non-profit (founded 1998) that initiates and funds psychedelic neuroimaging and clinical research in collaboration with leading universities, while advocating for evidence-based drug policy reform globally.

What Beckley Foundation does

The Beckley Foundation is a UK-registered non-profit charity (SC033546) founded in 1998 by Amanda Feilding, headquartered at Beckley Park, Oxford. Its scientific programme initiates, designs, and conducts research into the effects of psychoactive substances on the brain, with a particular focus on psychedelic compounds including LSD, psilocybin, ayahuasca/DMT, MDMA, and cannabis. The foundation's core technology stack combines neuroimaging modalities — fMRI, MEG, and optogenetic electrophysiology — with clinical trial design and novel research methodologies such as self-blinded microdosing surveys. It runs its flagship work through a long-standing partnership with Imperial College London (the Beckley/Imperial Research Programme, co-founded with Prof David Nutt in 2008), and maintains a network of more than 15 named university collaborations spanning the UK, continental Europe, the US, the Caribbean, and Brazil.

The foundation has produced over 35 peer-reviewed publications in high-impact journals including PNAS, Nature, Lancet Psychiatry, and Current Biology, including the world's first brain imaging study of the human brain on LSD (published 2016) and pioneering psilocybin trials for treatment-resistant depression showing 67% of patients in remission one week post-treatment. Its second core activity is drug policy reform advocacy: it has published major policy reports (Roadmaps to Regulation, Global Cannabis Commission), orchestrated open letters signed by world leaders and Nobel laureates, and holds a flagship advisory role with the Jamaican government on national cannabis regulation.

The business model is donation-funded non-profit: the foundation states that 'our ground-breaking work relies entirely on donations.' It currently reports paused receipt of donations. It does not sell products or services commercially; revenue derives from individual donations, crowdfunding, and research grants (e.g., a UK Medical Research Council grant for a Phase I psilocybin trial). Commercial activities bearing the Beckley name (Beckley Retreats, Beckley Psytech) operate as separate legal entities and are not part of the foundation itself. The foundation's customer base, in the conventional sense, is global and distributed across 40+ donor countries, with a small number of episodic government advisory relationships.

Beckley Foundation firmographics

Firmographics
Name
Beckley Foundation
Legal name
Beckley Foundation
Website
https://beckleyfoundation.org
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
1–10 employees
Short description
The Beckley Foundation is a UK non-profit (founded 1998) that initiates and funds psychedelic neuroimaging and clinical research in collaboration with leading universities, while advocating for evidence-based drug policy reform globally.
Ownership category
akta.pro rank

Beckley Foundation industry classification

Industry
Product category
Scientific Research and Policy Advocacy
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Psychedelic research
  • Drug policy reform
  • Neuroimaging studies
  • Clinical trials
  • Cannabis regulation

Where Beckley Foundation is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Beckley Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels3 records

Marketing channels7 records

Beckley Foundation product offering

Product offering

Core offering

The Beckley Foundation initiates, designs, and conducts scientific research into the effects of psychoactive substances on the brain and consciousness, using neuroimaging technologies such as fMRI and MEG. It develops therapeutic protocols for treatment-resistant mental health conditions involving psilocybin and other psychedelics, and produces evidence-based drug policy analysis for governments and international bodies.

Product overview

The Beckley Foundation is a UK-based non-profit charitable organization (registered SC033546) focused on psychedelic research and drug policy reform. The foundation does not offer commercial products or services. Its activities include conducting and funding scientific research into psychedelics (LSD, psilocybin, DMT, MDMA, cannabis), publishing research findings, advocating for drug policy reform, hosting conferences and events, and providing educational resources through its website, podcasts, newsletters, and publications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Beckley/Imperial Psychedelic Research Programme
  • Psilocybin-Assisted Psychotherapy Protocol

Quantifiable outcome

  • 67% of treatment-resistant depression patients achieved complete remission one week after psilocybin treatment, with 42% remaining depression-free after 3 months (patients had suffered from depression for average of 18 years)
  • +3 more outcomes

Companies that use Beckley Foundation

Customer profile

Segments3 records

Ideal customer profiles3 records

Beckley Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Beckley Foundation partnerships and signals

Strategic signal

Partnerships

24 partnerships are on record, tiered core, major, flagship and minor.

  • Imperial College LondoncoreStrategic or Co-development Partner · 1 January 2008Co-founded the Beckley/Imperial Psychedelic Research Programme with Prof David Nutt in 2008. This flagship collaboration has produced world-first neuroimaging studies including the first brain imaging study of LSD and pioneering psilocybin clinical trials for treatment-resistant depression. The programme has resulted in over 35 publications in high-impact journals.
  • University of BristolcoreStrategic or Co-development PartnerInitial collaboration began with Prof David Nutt at University of Bristol in 2005 before he moved to Imperial College London. Research focused on cannabis and psychedelics.
  • University College London (UCL)coreStrategic or Co-development PartnerCollaboration with UCL on cannabis research, including comparing effects of different cannabis strains with varying THC/CBD ratios using brain imaging technology. Also working on Jamaican cannabis research with University of the West Indies.
  • Johns Hopkins UniversitymajorStrategic or Co-development PartnerListed as a key collaboration partner in psychedelic research within the foundation's network of leading research institutions.
  • King's College LondonmajorStrategic or Co-development PartnerListed as a key collaboration partner in psychedelic research within the foundation's network of leading research institutions.
  • Beckley/Sant Pau Research Programme (Barcelona)coreStrategic or Co-development PartnerCollaboration with Dr Jordi Riba focusing on ayahuasca research. This programme discovered that ayahuasca alkaloids stimulate neurogenesis in neural stem cells.
  • MAPS (Multidisciplinary Association for Psychedelic Studies)majorStrategic or Co-development PartnerCo-hosted Psychedelic Science 2017 conference in Oakland, California together with MAPS. This major international scientific conference brought together the international psychedelic research community.
  • Jamaican Ministry of JusticeflagshipStrategic or Co-development PartnerAmanda Feilding was invited by Minister Mark Golding in 2015 to advise the Ministry of Justice on formation of balanced policies for cannabis industry regulation in Jamaica. This advisory role has shaped Jamaica's pioneering approach to cannabis regulation.
  • Jamaican Ministry of Industry, Investment & CommerceflagshipStrategic or Co-development PartnerPartnership with the Ministry on the conference 'Jamaica's Regulated Cannabis Industry: First Steps' and ongoing advisory work on developing cannabis regulation frameworks.
  • University of the West IndiesmajorStrategic or Co-development PartnerCollaboration planned for investigating biochemical composition of Jamaican cannabis landrace strains and identification of strains with optimal medical benefits.
  • Cannabis Licensing Authority (Jamaica)majorStrategic or Co-development PartnerCollaborating with Jamaica's Cannabis Licensing Authority as part of advisory work on developing the regulated cannabis industry framework.
  • Exeter UniversityminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Cardiff UniversityminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Freiburg UniversityminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Hannover Medical SchoolminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Beckley/Sechenov Institute Research Programme (Russia)minorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Medical Office for Psychiatry and Psychotherapy, SolothurnminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Madrid Computense UniversityminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Maastricht University (Beckley/Maastricht Research Programme)minorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Beckley/Brazil Research ProgrammeminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Ethnobotanicals Research ProgrammeminorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions focusing on ethnobotanical substances.
  • ICEERS (International Center for Ethnobotanical Education, Research & Services)minorStrategic or Co-development PartnerListed as a collaboration partner in the Beckley Foundation's network of research institutions.
  • Harvard Law SchoolmajorStrategic or Co-development PartnerProfessor Charles Nesson from Harvard Law participated in the Beckley Foundation delegation to UNGASS and conducted interviews on drug policy issues.
  • Walacea.comminorOthersCrowdfunding platform used for the world-first LSD brain imaging study campaign in 2015, raising £25,000 in 45 days.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Beckley Foundation competitors and assessment

Company assessment

Direct peers

  • Heffter Research Institute: US-based non-profit funding psychedelic (especially psilocybin) research at academic institutions. Directly comparable funder/research-catalyst role within the psychedelic ecosystem.
  • MAPS (Multidisciplinary Association for Psychedelic Studies): US-based non-profit conducting psychedelic clinical research and drug policy advocacy. Direct peer on both research (psychedelic-assisted therapy, MDMA for PTSD) and policy reform dimensions, and an existing Beckley co-host of Psychedelic Science 2017.
  • Johns Hopkins Center for Psychedelic and Consciousness Research: Academic psychedelic research centre that is a listed Beckley partner and produces parallel psilocybin clinical trials. Comparable scope (psilocybin for depression, addiction, smoking cessation) and publication output.
  • Imperial College Centre for Psychedelic Research: Co-hosts the flagship Beckley/Imperial Research Programme; conducts neuroimaging and clinical psychedelic studies with the same principal investigators (Nutt, Carhart-Harris). Operationally the most overlapping peer.
  • Usona Institute: Non-profit psychedelic research sponsor focused on psilocybin for major depressive disorder. Comparable mission, non-profit structure, and clinical trial sponsorship model.
  • International Drug Policy Consortium (IDPC): Global network of NGOs working on drug policy reform. Closely aligned on the policy-advocacy dimension of Beckley's mission and a frequent collaborator at UN and government forums.

Emerging players

  • Drug Science: UK-based independent scientific body chaired by Prof David Nutt (Beckley's principal collaborator). Closely adjacent on drug science and policy reform, with overlapping scientific leadership.
  • Beckley Psytech: Commercial psychedelic medicine company spun out of the Beckley ecosystem, led by Cosmo Fielding Mellen (Amanda Feilding's son). Operationalises psychedelic research into commercial drug development — adjacent mission, separate legal entity.

Broad incumbents

  • Compass Pathways: Publicly listed psychedelic therapy company developing psilocybin for treatment-resistant depression. Comparable clinical target; operates at substantially larger commercial scale than Beckley's research programmes.
  • MindMed: Publicly listed psychedelic and digital therapeutic company developing LSD, MDMA, and DMT-based therapies. Competes for talent, partnerships, and policy influence in the same research domain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Beckley Foundation social profiles

Digital presence

Beckley Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beckley Foundation leadership team

Management profile

Number of profiles

Profiles2 records

Beckley Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beckley Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beckley Foundation

What does Beckley Foundation do?

The Beckley Foundation initiates, designs, and conducts scientific research into the effects of psychoactive substances on the brain and consciousness, using neuroimaging technologies such as fMRI and MEG. It develops therapeutic protocols for treatment-resistant mental health conditions involving psilocybin and other psychedelics, and produces evidence-based drug policy analysis for governments and international bodies.

Is Beckley Foundation a public or private company?

Beckley Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Beckley Foundation founded?

Beckley Foundation was founded in 1998. It employs 1 to 10 people.

Where is Beckley Foundation based?

Beckley Foundation is headquartered in Oxford, United Kingdom, in the Europe region.

Who are Beckley Foundation's main competitors?

Direct peers on record are Heffter Research Institute, MAPS (Multidisciplinary Association for Psychedelic Studies), Johns Hopkins Center for Psychedelic and Consciousness Research, Imperial College Centre for Psychedelic Research, Usona Institute and International Drug Policy Consortium (IDPC). Emerging players are Drug Science and Beckley Psytech. Broad incumbents are Compass Pathways and MindMed.

Does Beckley Foundation have an API?

No public API is recorded for Beckley Foundation.

What industry is Beckley Foundation in?

Beckley Foundation's product category is Scientific Research and Policy Advocacy. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MeerTiny doses, big questions in the future of mental healthThis article provides an overview of microdosing psychedelics as an emerging mental health treatment approach, examining the scientific evidence, clinical trials, and ethical considerations surrounding the practice. Key institutions discussed include Italy's SIMEPSI, which received regulatory approval from AIFA for the country's first psilocybin clinical trial treating treatment-resistant depression, and Germany's OVID Clinic, which offers psychedelic-assisted therapies under medical supervision. The piece highlights ongoing research initiatives at Imperial College London, Beckley Foundation, MindMed, and Usona Institute, while noting that rigorous placebo-controlled trials remain limited and mainstream adoption requires further scientific validation.GlobeNewswireDoes Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen InvestigatesThe Beckley Foundation and Quantified Citizen launched a study to examine how microdosing affects meditation practice over three months. The study, part of the Microdose.me project, has over 20,000 participants and aims to guide future research on safety and benefits.UKTNThis psychedelic medicine company wants to treat psychiatric and neurological disorders - UKTNBeckley Psytech raised £14M in equity funding from Noetic Psychedelic Fund LP and Bail Capital. The company will use the funds to develop psychedelic drugs for psychiatric and neurological disorders, with the first phase of a clinical trial on synthetic 5-MeO-DMT planned.HuffPostMicrodosing LSD Is A Growing Silicon Valley Trend. But Does It Actually Work?Researchers are launching a placebo-controlled trial of microdosing LSD, supported by Imperial College London and the Beckley Foundation. The study uses self-blinding with online recruitment and aims to test whether the practice delivers claimed benefits or is a placebo effect.PR NewswireGlobal Cannabis Research Leaders Beckley Foundation and Canopy Health Innovations Partner to Form Beckley Canopy TherapeuticsCanopy Growth and Beckley Foundation formed Beckley Canopy Therapeutics to develop cannabis-based medicines. The partnership will conduct a brain imaging trial on a proprietary cannabinoid, with additional research starting in 2018. Profits from commercialized products will support the Beckley Foundation.New York PostResearchers are using LSD to treat depressionResearchers in the UK will test LSD to treat depression, giving 20 volunteers four doses and measuring mood and Go game performance. The $400,000 trial, led by the Beckley Foundation, compares results to placebos. If successful, the group plans to seek government funding for a larger experiment.The Independent'My fear of dying was gone': Former cancer patient says psychedelic drugs helped him cope with end of life anxietyRodrigo Niño, a former cancer patient, took ayahuasca in the Amazon to cope with end-of-life anxiety, reporting his fear of dying vanished. He now funds research into psychedelics like MDMA and LSD, citing studies showing psilocybin reduces depression in cancer patients. He advocates for medicalization, not legalization.The IndependentScientists are about to find out how Silicon Valley's LSD habit really affects productivityAmanda Feilding and colleagues will begin a study later this year examining microdosing effects on creativity and cognition. The study will test 20 participants with four LSD doses (0, 10, 20, 50 micrograms) over four days, with results expected by year-end. No existing study has examined microdosing science.